PMID: 16619447Apr 20, 2006Paper

California Stem Cell Research and Cures Act: what to expect from stem cell research?

The Journal of Biolaw & Business
Joe PanettaMichelle Mehok

Abstract

On November 2, 2004 California voters approved Proposition 71, the California Stem Cell Research and Cures Act ("Act"), a $3 billion bond measure to advance stem cell research over the next ten years. The Act also created the California Institute for Regenerative Medicine (CIRM) and the Independent Citizens Oversight Committee (ICOC) which will govern the Institute, and make grants and loans for stem cell research and research facilities. This article will cover the history of the "Act", its potential impact on NIH's current stem cell program, and what are other states doing to compete with California's revolutionary efforts. In addition, the article will discuss the criteria for California's grant applicants under the Act and the legal issues surrounding the new discoveries funded by the Act.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.